| Primary |
|
| Renal Failure Acute |
100.0% |
|
| Secondary |
| Atrial Fibrillation |
16.4% |
| Product Used For Unknown Indication |
12.6% |
| Arrhythmia |
11.3% |
| Cerebrovascular Accident Prophylaxis |
8.2% |
| Drug Use For Unknown Indication |
8.2% |
| Epilepsy |
7.5% |
| Cardiac Failure |
6.3% |
| Atrial Flutter |
3.1% |
| Hypertension |
3.1% |
| Anaesthesia |
2.5% |
| Essential Hypertension |
2.5% |
| Hypothyroidism |
2.5% |
| Myocardial Ischaemia |
2.5% |
| Pain |
2.5% |
| Pain In Extremity |
2.5% |
| Bronchopneumonia |
1.9% |
| Depression |
1.9% |
| Lung Disorder |
1.9% |
| Anaemia Folate Deficiency |
1.3% |
| Dyslipidaemia |
1.3% |
|
| Vomiting |
14.8% |
| Thrombocytopenia |
11.1% |
| Weight Decreased |
11.1% |
| Cerebrovascular Accident |
3.7% |
| Drug Interaction |
3.7% |
| Electrocardiogram Qt Prolonged |
3.7% |
| Fall |
3.7% |
| Hyperthermia |
3.7% |
| Hyponatraemia |
3.7% |
| Metabolic Acidosis |
3.7% |
| Nausea |
3.7% |
| Oestradiol Increased |
3.7% |
| Renal Failure |
3.7% |
| Renal Failure Acute |
3.7% |
| Renal Impairment |
3.7% |
| Septic Shock |
3.7% |
| Somnolence |
3.7% |
| Staphylococcal Sepsis |
3.7% |
| Subcutaneous Haematoma |
3.7% |
| Urinary Retention |
3.7% |
|
| Concomitant |
| Hypertension |
17.4% |
| Product Used For Unknown Indication |
17.1% |
| Atrial Fibrillation |
15.3% |
| Cardiac Failure |
7.9% |
| Cardiac Failure Chronic |
5.5% |
| Cardiac Disorder |
5.3% |
| Diabetes Mellitus |
3.2% |
| Pain |
3.2% |
| Transitional Cell Carcinoma |
2.6% |
| Arrhythmia |
2.4% |
| Cardiac Failure Congestive |
2.4% |
| Colorectal Cancer Metastatic |
2.4% |
| Prophylaxis |
2.4% |
| Depression |
2.1% |
| Osteoporosis |
2.1% |
| Tachycardia |
2.1% |
| Cerebrovascular Accident Prophylaxis |
1.8% |
| Lung Neoplasm Malignant |
1.8% |
| Anticoagulant Therapy |
1.6% |
| Idiopathic Thrombocytopenic Purpura |
1.6% |
|
| Renal Failure Acute |
11.7% |
| Weight Decreased |
11.7% |
| Thrombocytopenia |
10.0% |
| Death |
6.7% |
| International Normalised Ratio Increased |
6.7% |
| Prothrombin Time Shortened |
5.0% |
| Sepsis |
5.0% |
| Abdominal Distension |
3.3% |
| Cardiac Failure Acute |
3.3% |
| Colitis |
3.3% |
| Dementia |
3.3% |
| Febrile Neutropenia |
3.3% |
| Hyponatraemia |
3.3% |
| Ischaemic Stroke |
3.3% |
| Liver Injury |
3.3% |
| Oesophageal Ulcer |
3.3% |
| Pain In Extremity |
3.3% |
| Pneumonia |
3.3% |
| Prothrombin Time Prolonged |
3.3% |
| Purpura |
3.3% |
|
| Interacting |
| Cardiac Failure |
38.5% |
| Arrhythmia |
7.7% |
| Bronchitis |
7.7% |
| Depression |
7.7% |
| Dyslipidaemia |
7.7% |
| Hyperglycaemia |
7.7% |
| Hypertension |
7.7% |
| Product Used For Unknown Indication |
7.7% |
| Type 2 Diabetes Mellitus |
7.7% |
|
| Drug Interaction |
50.0% |
| Therapeutic Agent Toxicity |
25.0% |
| Visual Acuity Reduced |
25.0% |
|
